

.....  
(Original Signature of Member)

114TH CONGRESS  
1ST SESSION

**H. R.** \_\_\_\_\_

To authorize the use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law, and for other purposes.

\_\_\_\_\_  
IN THE HOUSE OF REPRESENTATIVES

Mr. SALMON introduced the following bill; which was referred to the  
Committee on \_\_\_\_\_

\_\_\_\_\_  
**A BILL**

To authorize the use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Right to Try Act of  
5 2015”.

1 **SEC. 2. USE OF UNAPPROVED MEDICAL PRODUCTS BY PA-**  
2 **TIENTS DIAGNOSED WITH A TERMINAL ILL-**  
3 **NESS.**

4 (a) IN GENERAL.—Notwithstanding the Federal  
5 Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.),  
6 the Controlled Substances Act (21 U.S.C. 801 et seq.),  
7 and any other provision of Federal law, the Federal Gov-  
8 ernment shall not take any action to prohibit or restrict  
9 the production, manufacture, distribution, prescribing,  
10 dispensing, possession, or use of an experimental drug, bi-  
11 ological product, or device that—

12 (1) is intended to treat a patient who has been  
13 diagnosed with a terminal illness; and

14 (2) is authorized by, and in accordance with,  
15 State law.

16 (b) DEFINITIONS.—In this section:

17 (1) The term “biological product” has the  
18 meaning given to such term in section 351 of the  
19 Public Health Service Act (42 U.S.C. 262).

20 (2) The terms “device” and “drug” have the  
21 meanings given to such terms in section 201 of the  
22 Federal Food, Drug, and Cosmetic Act (21 U.S.C.  
23 321).

24 (3) The term “experimental drug, biological  
25 product, or device” means a drug, biological product,  
26 or device that—

1 (A) has successfully completed a phase 1  
2 clinical investigation;

3 (B) remains under investigation in a clin-  
4 ical trial approved by the Food and Drug Ad-  
5 ministration; and

6 (C) is not approved, licensed, or cleared for  
7 commercial distribution under section 505,  
8 510(k), or 515 of the Federal Food, Drug, or  
9 Cosmetic Act (21 U.S.C. 355, 360(k), 360(e))  
10 or section 351 of the Public Health Service Act  
11 (42 U.S.C. 262).

12 (4) The term “phase 1 clinical investigation”  
13 means a phase 1 clinical investigation, as described  
14 in section 312.21 of title 21, Code of Federal Regu-  
15 lations (or any successor regulations).

16 (5) The term “terminal illness” has the mean-  
17 ing given to such term in the State law specified in  
18 subsection (a)(2).